

200 mg/vial

CIMZIO

CIMZIA® (certolizumab pegol) In-Office Injection CIMplicity Savings Program



Indications

CIMZIA is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). CIMZIA is indicated for the treatment of adult patients with active psoriatic arthritis (PsA). CIMZIA is indicated for the treatment of adult patients with active ankylosing spondylitis (AS). CIMZIA is indicated for reducing signs and symptoms of Crohn's disease (CD) and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. CIMZIA is indicated for the treatment of adults with active psoriasis (PSO) or active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. CIMZIA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis (PSO) who are candidates for systemic therapy or phototherapy.

Important Safety Information

Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (such as Legionella or Listeria). Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member. CIMZIA is not indicated for use in pediatric patients.

Please see additional Important Safety Information on back cover and full Prescribing information provided by the UCB representative, and visit www.CIMZIAhcp.com.





Helping Eligible Patients Save on Out-of-Pocket Costs for CIMZIA® (certolizumab pegol) In-Office Injection

The CIMplicity Savings Program helps eligible, commercially insured patients save on their out-of-pocket costs for CIMZIA*

- Simplified patient enrollment process
- No income requirements
- No dollar limit per use

CIMplicity Savings Program information


Program website:

CIMZIA Support Phone Line:

ioa.cimziasavingsprogram.com

For questions, please call 1-877-705-4119 toll-free, Mon – Fri from 8:00 AM – 8:00 PM ET

Contact your Field Reimbursement Executive for more information.



* Eligibility: Available to individuals with commercial prescription insurance coverage for CIMZIA. Not valid for prescriptions that are reimbursed, in whole or in part, under Medicare (including Medicare Part D), Medicaid, similar federal- or state-funded programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), or where otherwise prohibited by law. Product dispensed pursuant to program rules and federal and state laws. Claims should not be submitted to any public payer (ie, Medicare, Medicaid, Medigap, TRICARE, VA, and DoD) for reimbursement. The parties reserve the right to amend or end this program at any time without notice.

The CIMplicity Savings Program Is Managed Through an Online Portal

The online portal enables claims submission and payment via Electronic Funds Transfer (EFT).

- Enrollment for new offices via online portal at ioa.cimziasavingsprogram.com
- Patient enrollment and claim submission through portal
- Copay claims paid via EFT to appropriate bank account
- Bank reconciliation number and amount is listed by date, patient, and claims for all transactions

cimziq						
Home Physician	Patient	Clain	Payment Reconciliation	Reinbursement Type	User Management	Guide and FAQs +
Welcome to the Co-Pay Sav	ings Program Web Portal	1				
For patients who receive Cinaia" (certai program, enroll your autients, and enter		the Cinuia Co-Pay Sa	ings Program can help cover	out of pocket costs. This	portal allows your facility to	eval in the
Click here to greate an account or	enter your Username and Pas	sword below:				
Account Information			1			
Usemane or Email Address Password						
Lagin.						
A	vgat Your Password?		1			
Enter your Username or Email A	ddress to receive your password	L.				
Username or Email Address:						
		label				

• Log-in with username or email and ability to retrieve forgotten passwords

The online portal now allows for:

- Site administrators to add secondary users to perform certain functions
- Account administrators to update their own banking information as needed
- Improved sorting and tracking on reconciliation screens, including claim ID
- Ability to add associated practices for accounts with referring practices/physicians

cimzia				258965 Rancho 1 ed at teotôrieda 6321212 Fax 6	lahet, ELC bbaga, Mission Vej ff.carii W3321213	2, CA - 900H		
Home Physician	Patient	t Clains	Payment Reconciliation	Asinbursene	et Type User	Managers	HE I	Juide and F/
User Management The following list of people have acce	ax to the practice ac	count on this website. One	leid. Use Enter key or click Saw				will receive	notification
confirming EQB submissions and dep	calts via their select		n method.		la Site			
Joe Smith	215-555-6789	Joe Smith@ThisMedicaPra		Unlocked	Administrator	(United)	144	[Deleto]
Mary Jones	215-555-6788	Mary Jones @ThisMedicalPr	acticeName.com	Unlocked		Unlock	[B4K]	Deleta
Bill Nyo	215-555-6787	BillNye@ThisMedicaPracti	ceName.com	Locked		(Prink)	Cer.	Deleta
Tom Jones	215-555-6786	Tom Jones@ThisMedicaPo	cticeName.com	Unlocked		Unicol	194	[Deble]
Contact Name: *	Phone Number: 215-655-6787		Email Address: * Elit Nyell ThisMedicalPracticeN Liser Name: Elit Nyell ThisMedicalPracticeN Environment of MedicalPracticeN Internet of MedicalPracticeN	iame.com	 *>	lite Adminis		
(or)	lanos						Yes	painst forth
unnation You Should Knew About CINZI								

Please see additional Important Safety Information on back cover and full Prescribing information provided by the UCB representative, and visit www.CIMZIAhcp.com.





ENROLLMENT FOR NEW OFFICES



5

Select the "create an account" link on the CIMplicity Savings Program portal (ioa.cimziasavingsprogram.com).


2 Complete all fields. Under Reimbursement Type, select "EFT."

3 Enter all banking information and check the box indicating you agree to all terms. Click submit.

Select **Physician** tab and enter physicians.

At this point, you have successfully enrolled.

Allow 5 to 7 business days for completion of EFT setup. You will receive an email stating EFT-Verified when the EFT registration process is complete. The notification will also be shown on the top right information bar of the portal stating EFT-Verified.



SWITCHING FROM DEBIT CARDS TO EFT

Log in to the new CIMplicity Savings Program portal (ioa.cimziasavingsprogram.com) using your existing username and password.

Select the **"click here"** hyperlink in the yellow box to change reimbursement type.

	Tyskias Paleri	Claim	Payment Percentitation	Beindunseheid Type User Maragen	ent Guide and Migs 14
Co-Pay Savings Prog	ram				
Welcome to the homes	0.08				
A Conty of It you	ument reimbursement type is ne reimbursement type may i have any questions, please ci e <u>click here</u> to change reimbu	be used. ALL future o all 1-877-705-4119 fo	taims will be proces	ge or enroll in a different reimburser used using the selected reimbursers	ment type. ent type onlyt
Update Existing Pre	ctice Information			Update Existing Patient Information	a
Enroll a Physician				Submit a Claim	
Update Existing Phy	sician Information			View Claim Status	
Enroll a Patient				Payment Reconciliation	
Beimburgement Top	•			Enter/Add a new Control Card ID	
				User Management	
If you need more IO	kits, please send your reque	it with contact and a	ddress information	to IOIcopayordering@connectiverx.	som
For additional quest Manager directly.	ions, please call 1-877-705-41	19, email IOIofficesu	pport@connectiverx	.com, or contact your UCB Field Re	inbursement

You will now be taken to the **EFT registration form,** where you must complete your banking information.

Click **"submit"** to complete your EFT registration.

	Antonio antoni
	same for fair is fair the frie by a stirt fee lipide also have been a serpleter
Excellment for Electronic Pands Transfer (EPT)	
hand a firm	- victor was
Rub's 1950a, 1/0	Cristen Recite States
National Partice Inter-	B ann Backson
to pass par production states and	
a P ² bitro strate of the discontent	
Little in the first large	81 Michaeleneriaettere 1
T Directorers Instates: *	87 Oles Generic Para Notion *
option famous PT Mitp Const. top to attack the asset	
time because, 011 into camen fractional	Approval feature of \$100 million (cancer) can that the
tion feature, PT Min Generic End Address	Sector Internet Sectors, MY Mile Conner's Proce Sector
Basking Information	
Nerve of Autors - Proving North	Annual and a
	NOT T
the approximation of the second	
hand a carry attack by the	and the set of the set
	10/27 10/20
lapara pranca y P	
a setterine Print I.S. an instant of hard and in additional instantion	a) Surgery's triches only that execut articles is the found influence parket with tracpose of party
	an a the france of the constant process and reads, or and reads and the france of the france of the and any optimizers.
	nan panamenta autoriadar, as al perspis alminea langung te tha anam of autorading analog langung an
a autorization germativenio adi semati in affect anti sa tatifi di minana il argitterizatione praesang giantific acto integrary in	entrary is unity of the desired in a point and exclusion are unit (any pay) solida as the set automatication in the last of desired in with an administration regimes (as some introduced particular soliday) modes of any administration in the last of the last of the iso point of them not a second M days, building and a thermatication strategies better (any payments and secondaria exclusion) granted from the the secondaria soliday point (as the secondaria soliday) and the secondaria exclusion granted from the the secondaria parameters (particular) as the secondaria of the secondaria exclusion granted from the the secondaria parameters (particular) as the secondaria of the secondaria point of the the the secondaria of the secondaria soliday (particular) and (
	uterioale penaltani i unanti di manti, ta te te anut pulla teni i untaini parametati te terito teni i unanti uni trittari uni administrati atprovingusti iterake si administra te ini.
e undersystel that, access to the antert accessely provided ethanics reparty, Company with face to leading to be for ally enhangements with demapter actually incomed by an tet fourneed the actualt of a	as personnes applicable loss. Fary, reade made benarder by lampary is improperly initiated through the topippers of relates estimates parents or other arrive decoupts, and say the lambas calendars for such califying and a terminal is any construction.
provident of this authorization can be attached or unitself, actions	auto another a value is activity in a unity specify income your as
the advertising provides have a reconstruct with any opplication and all and providers as provides.	ion, such insolute control, and such produce and he resulted to comply with such insolution presenting as much of the original
	e and the prime strate prior where the internation columnstic (surgery is consuming with our requiring reading present
Ta advance.	
dani	Topolo Series
100	

AFTER SUCCESSFULLY ENROLLING IN EFT:

- Any claims already in process will continue through the current review process using the Visa® debit card
- Your account will state **EFT-Pending** for 5 to 7 business days
- You will receive a notification stating EFT-Verified when the EFT registration process is complete.
 The notification will also be shown on the top right information bar of the portal stating EFT-Verified
- All claims entered thereafter will be paid via EFT
- The identifier on your office's bank statement will be "copaysavingsprogram"

Please see additional Important Safety Information on back cover and full Prescribing information provided by the UCB representative, and visit www.CIMZIAhcp.com.

Visit our website: ioa.cimziasavingsprogram.com






5




On the CIMplicity Savings Program portal homepage, navigate to the **"Patient"** tab or select the **"Enroll a Patient"** hyperlink.



5

Provide the patient with a copy of the **patient kit**, which provides information on the CIMplicity Savings Program.

	Patient Kit (certolizumab pegol)
Program Eligibility Rules CIMZIO (certelizement pepel)	WELCOME to the Co-Pay Savings Program!
The associated CoPay Savings Program is valid for out-of-pocket expenses for CIMZIA® (aetalizzmab pegal) per current Program rules. Offer is not valid for any other products	In-Office Injection
is of eter and pickel roads, even if Netse casts are associated with the injection of a down of AURA Frynerius relates to dawn enforced and abundance of a subjectation of a down the assumption of the analytic grade and an analytic and an analytic and posterior and an analytic and an analytic and an analytic and an analytic and analytic and the analytic and an analytic and analytic and analytic and an an an a	 You on eligible to rective CMLAM (profilement page) via incidine injection. The CMLAM CaPty Soring: Program can help cover your out-dipodet costs. An enable of the cliffice avoid by via inch de CaPty Soring: Program. There is no coditional color models from syste, the file was warded by the syste manage your participation in the Program Perticipation A conclinent into the Program for claim submission A strength of the file strength with the system analogs of the class of the Program for the size analogs of the Program for the size and strength of the size of the class of the Program for the size analog of the Program for the size analogs of the program for the size analogs of the program (size and size an
CMZAF is a registered trademark of the UCB Group of Companies. 19 2018 UCB, Inc. All rights reserved. USPCZ031500113g1[a	CMDA can lower the child'y of your immune system to fight infection. Some people who received CMDA have developed strong infections, including Materials and an infections caused by vincess, fample of bactrick that have speed throughout the supplicitation and death.



*50474-0710-81, CIMZIA Prefilled Syringe Starter Kit; 50474-0700-62, Lyophilized Powder; 50474-0710-79, Prefilled Syringe.

Please see additional Important Safety Information on back cover and full Prescribing information provided by the UCB representative, and visit www.CIMZIAhcp.com.





CHECKING STATUS OF A CLAIM

- Navigate to the "Claim" tab.
- 2 Select the applicable physician, patient, and patient ID. The patient claim history will be shown.

Beinhursement Type Status: EFT-Verlied LAMS Outer Payers Club Payers Mark and 76.0 Outer Status Face Status	cimzia						Address: 2 Contact: F	dame: Me 2258365 Fred at fr	edical Affiliates, LLC	ission Vejo, CA - 90066	ractice] (Liser Ma	(trameau
LANS							Reim	burse	ment Type SI	atus: EFT-Verified	d	
LANS LANS LANS LANS LANS LANS LANS LANS	Home	Physician		Patient	Claim	Payment Re	conciliation	Reim	bursement Type	User Management	Guide ar	nd FAQs 🔸
operation operation <thoperation< th=""> <thoperation< th=""> <tho< td=""><td>CLAIMS</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tho<></thoperation<></thoperation<>	CLAIMS											
Ance: Badantized - Cline hardred 2 and 2 a	Physician:		Select Phy	sician	B			_				
Brain (2017) ar uption will able class schemation, jakent mich ze registration Image: Class schematic registration Image: Class schematic registration andrear Durit	Patient:		Select Pati	ient		Add Claim		s	ubmitted - Offic	e has entered claim		
Approved Funded - Claim has been appril Approved Funded - Claim has been appril Devised - Data Devised - Claim has been appril Devised - Data Devised - Claim has been appril Devised - Data Devised - Claim has been appril Devised - Data Devised - Data		ì	Y using EDI th	ne system will add o	claim information, patier	nt must be registe	ared	-			Councils DET D	
Denied - Cam rejected International / Not much have Road on your computer International / Road on your computer Internation / Road on your	Member ID:		Select Pati	and ID				A	pproved/Funde	d – Claim has been app		
	Reimbursement.	Date_	- / · · · ·	tputer Patient	Patient	Member ID	Glaim	D	t Date.	Pate Swiped/EFT (
EFT 04/15/2015 In Review Connor Pain 65048970300 500.25 0.00			- / · · · ·	nputer		Member ID	Claim	Þ				
Data 0211/0215 Approved Connor Pain #5048970303 0.01 0.02 Mar.	Reimbursement. Tres of	Date Service	Status	iputer Patient. First Name	Patient Last Name		Claim Amount 85.00	Amount	t Date.	Pate Swiped/EFT (
	Beimburaement. Tros ef. EFT 03	Date Service V15/2015 S	Status Submitted	iputer Entitent Entit Name William	Patient Last Name Kneep	45048970293		0.00	t Date.	Pate Swiped/EFT (View
	simbursement, Tros ef EFT 03 EFT 04	Date. Service V15/2015 S V15/2015 I	Stintus Submitted In Review	Patient Eastent First Name William Connor	Patient, Last Name Kasep Pain	45048970293 65048970300	500.25	0.00	t Date.	Pate Swiped/EFT (Vev

- Each patient claim entered will initially state **PENDING**.
- When the claim processor starts reviewing the claim against the EOB and program business rules, the claim status will state QC.
- When the review is complete, the patient claim information will state **APPROVED** or **DENIED**.
- When approved and processed, you will see the date that funds are deposited and the bank tracking number.
- A letter or email will be sent to the office and patient to verify the amount approved or the reason for claim denial.

After the patient EOB is submitted, the processing and payment of a claim will take up to 5 days.



1	Navigate to the "Payment		Use of this ports	l is restricted	i to authorized m	edical office Patient	e personnel.	Please do n Claim	not allow t		Welcome June Practice Nam Address: 225 Contact: Fred Phone: 69833	e: Medical Affilia	at Change Pa ées, LLC bago, Mission V com 53321213	assecti [Lipda Ago, CA - 90055	
	Reconciliation" tab.	P C P	To print out a reco Paryment Reco D date of Service Hysicians: Patients: associated Vactice: DESPLAY DATA	Defe of D John X Ken X Medical All	N eposit Start Da	fa	to End I	Date	j	Select Recon Debit ONLY Control Car O Electronic F QBOTH Debi	rd ID# 696	03416515 x]			
	Select the Date of		CLAIM DATA										EXPORT as	9 PDF	EXPORT 10 EXCB.
2)			Mandonik ()	Extinct. Exat Name	Entert Date	01.01/1910	0101/2010	Stoco Di	Deacest. Ente	Ciain. C	Bank Trace. Namber	Sentral Card. B	Etonisian. Last Name	Entisian EntiNama	Marcine Discher Die State Discher Discher Die State Discher Discher Die State Discher
	Service or Date of		12345578901	JOHN	DOE	01/01/1910	01/01/2010	\$1000 01	1.01/2010	00000000000	00000000000	000000000000	ADAMS	PAUL	Medical Affiliates, LLC
			12345678901	JANE	DOE	01/01/1910	01/01/2010	\$2000 01	1.01/2010	00000000000	000000000000	000000000000	WALKER	GEORGE	Medical Affiliates, LLC
	Deposit.		12345678962	TOM	SMITH DOE	01/01/1910	01/01/2010	\$1000 01	1012010	00000000000	00000000000	000000000000000000000000000000000000000	JONES ADAMS	JOHN	Medical Attilates, LLC
			12345678903	HARRY	DOE	01/01/1910	01/01/2010	\$1000 01	101/2010	0000000000	00000000000	00000000000	WALKER	GEORGE	Medical Affiliates, LLC
			0000000004	MKE	SMITH	01/01/1910	01/01/2010	\$2000 01	1.01/2010	00000000000	00000000000	000000000000	JONES	JOHN	Medical Affiliates, LLC
			12345578905	SARA	DOE	01/01/1910	01/01/2010	\$2000 01	1.01/2010	00000000000	00000000000	000000000000	ADAMS	PAUL	Bhatla Group
			12345678906	JANE	DOE SMITH	01/01/1910	01/01/2010	\$1000 01	1.01/2010	00000000000	000000000000	000000000000000000000000000000000000000	WALKER JONES	GEORGE	Bhatia Group Bhatia Group
	Select the Physician(s) ,		12345678901	JOHN	DOE	01/01/1910	01/01/2010	\$1000 01	1.01/2010	00000000000	00000000000	00000000000	ADAMS	PAUL	Bhatla Group
3)			12345678901	JANE	DOE	01/01/1910	01/01/2010	\$2000 01	101/2010	00000000000	000000000000	000000000000	WALKER	GEORGE	Burnette Medical
	Patient(s), and		00000000000	JOHN	SMITH	01/01/1910	01/01/2010	\$2000 01	101/2010	00000000000	00000000000	00000000000	JONES	JOHN	Burnette Medical
	Associated Practice(s).	Important Safety Infor	12345678901	JANE	DOE	01/01/1910	01/01/2010	\$1000 01	1012010	0000000000	00000000000	0000000000	WALKER	GEORGE	Burnette Medical

Select the

Reconciliation Payment Option (debit, EFT, or both).

5

You have the option to export as either a **PDF** or **Excel**[®] document, and also the option to print a reconciliation document.

Please see additional Important Safety Information on back cover and full Prescribing information provided by the UCB representative, and visit www.CIMZIAhcp.com.





FREQUENTLY ASKED QUESTIONS

- Is my office required to enroll in EFT? Your office is not required to enroll in EFT. You can stay
 in the Visa debit card program if you wish; however, if you do switch to EFT, you can no longer
 use the Visa debit card program.
- 2. How many administrators under the same account can be on the portal? Only one email address can be submitted for each account. One person from the practice must be designated as site administrator; however, multiple users under the same account can have access to the portal.
- **3. How long will it take for my EFT registration to be processed?** Once an account registers, there is a 5 to 7 day response time from the bank. Once the portal says EFT-Verified, it is ready to process.
- 4. After my registration is complete, how long will it take from claim submission to payment? When sending a claim, there is a clean claim* processing time of approximately 24 to 48 hours. Payment from the bank would be 2 days thereafter. Normal claim transactions will take up to 5 days.
- 5. Can eligible patients use the CIMplicity Savings Program to meet their insurance deductible? Yes. The CIMplicity Savings Program can be used for out-of-pocket expenses for CIMZIA[®] (certolizumab pegol), including copayments, co-insurance, and deductibles. This program cannot be used for ancillary medical costs such as doctor visits or administration expenses.
- 6. Can the patient receive reimbursements through the CIMplicity Savings Program while he/she is simultaneously participating in another CIMZIA support program? No.

CIMZIA patients may participate in only one CIMZIA Savings Program for reimbursement of out-of-pocket expenses at any given time. If the patient stops receiving CIMZIA via in-office administration and switches to self- or home-administered treatment, a different program would be needed to provide copay support for pharmacy-filled prescriptions.

- 7. Is there a maximum amount the CIMplicity Savings Program will cover per injection? There is currently no limit per injection.[†] The patients pays as little as \$0 per dose.
- 8. Does the program stipulate a minimum number of days between injections? No. The program does not have a frequency restriction; however, insurance providers may have separate limitations that could affect frequency.

9. How long after a date of service can I submit a claim for reimbursement? All reimbursement requests must be submitted within 180 days of the date of service. Reimbursement requests for CIMZIA In-Office Injection out-of-pocket expenses not received within the 180-day limit may be rejected.

- 10. Is there a patient assistance program (PAP) for eligible patients who cannot afford this medication? Yes. There is a PAP program for eligible patients who have been prescribed CIMZIA. Please call CIMplicity[®] at 1-866-4-CIMZIA (1-866-424-6942). Select option 2, and a case manager will be happy to assist you.
- 11. What do I do if a patient has experienced an adverse event or has a product complaint? For adverse events, medical information, or product complaints, call 1-866-4-CIMZIA (1-866-424-6942) and select option 4.
- 12. Who is eligible for the CIMplicity Savings Program? The CIMplicity Savings Program is provided as a service of UCB for commercially insured patients and is intended to support the appropriate use of CIMZIA. Cash-paying and public payer funded patients are not eligible for the CIMplicity Savings Program. The CIMplicity program may be amended or canceled at any time without notice. Some program and eligibility restrictions may apply.[‡]

*Clean claim: all information was provided accurately with no questions on submission items.

[†] Subject to change.

[‡] Eligibility: Available to individuals with commercial prescription insurance coverage for CIMZIA. Not valid for prescriptions that are reimbursed, in whole or in part, under Medicare (including Medicare Part D), Medicaid, similar federal- or statefunded programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), or where otherwise prohibited by law. Product dispensed pursuant to program rules and federal and state laws. Claims should not be submitted to any public payer (ie, Medicare, Medicaid, Medigap, TRICARE, VA, and DoD) for reimbursement. The parties reserve the right to amend or end this program at any time without notice.

CIMplicity Savings Program information Program website:

ioa.cimziasavingsprogram.com

CIMZIA Support Phone Line:

For questions, please call 1-877-705-4119 toll-free, Monday through Friday from 8:00 AM – 8:00 PM ET

Contact your Field Reimbursement Executive for more information.

Please see additional Important Safety Information on back cover and full Prescribing information provided by the UCB representative, and visit www.CIMZIAhcp.com.





IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

CIMZIA is contraindicated in patients with a history of hypersensitivity reaction to certolizumab pegol or to any of the excipients. Reactions have included angioedema, anaphylaxis, serum sickness, and urticaria.

SERIOUS INFECTIONS

Patients treated with CIMZIA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue CIMZIA if a patient develops a serious infection or sepsis.

Reported infections include:

- Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before CIMZIA use and during therapy. Initiate treatment for latent TB prior to CIMZIA use.
- Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.
- Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

Carefully consider the risks and benefits of treatment with CIMZIA prior to initiating therapy in the following patients: with chronic or recurrent infection; who have been exposed to TB; with a history of opportunistic infection; who resided in or traveled in regions where mycoses are endemic; with underlying conditions that may predispose them to infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with CIMZIA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

- Do not start CIMZIA during an active infection, including localized infections.
- Patients older than 65 years, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants may be at greater risk of infection.
- If an infection develops, monitor carefully and initiate appropriate therapy

MALIGNANCY

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member. CIMZIA is not indicated for use in pediatric patients.

- Consider the risks and benefits of CIMZIA treatment prior to initiating or continuing therapy in a patient with known malignancy.
- In clinical trials, more cases of malignancies were observed among CIMZIA-treated patients compared to control patients.
- In CIMZIA clinical trials, there was an approximately 2-fold higher rate of lymphoma than
 expected in the general U.S. population. Patients with rheumatoid arthritis, particularly those
 with highly active disease, are at a higher risk of lymphoma than the general population.
- Malignancies, some fatal, have been reported among children, adolescents, and young
 adults being treated with TNF blockers. Approximately half of the cases were lymphoma,
 while the rest were other types of malignancies, including rare types associated with
 immunosuppression and malignancies not usually seen in this patient population.

Please see full Prescribing information provided by the UCB representative and visit www.CIMZIAhcp.com.



CLMZIA®, CLMplicity®, and cimplicity® are registered trademarks of the UCB Group of Companies. ©2024 UCB, Inc. Smyrna, GA 30080. All rights reserved. US-CZ-2400061

- Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including CIMZIA. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis, and the majority were in adolescent and young adult males. Almost all of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. Carefully assess the risks and benefits of treating with CIMZIA in these patient types.
- · Cases of acute and chronic leukemia were reported with TNF blocker use.

HEART FAILURE

 Worsening and new onset congestive heart failure (CHF) have been reported with TNF blockers. Exercise caution and monitor carefully.

HYPERSENSITIVITY

 Angioedema, anaphylaxis, dyspnea, hypotension, rash, serum sickness, and urticaria have been reported following CIMZIA administration. If a serious allergic reaction occurs, stop CIMZIA and institute appropriate therapy. The needle shield inside the removable cap of the CIMZIA prefilled syringe contains a derivative of natural rubber latex which may cause an allergic reaction in individuals sensitive to latex.

HEPATITIS B VIRUS REACTIVATION

- Use of TNF blockers, including CIMZIA, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers. Some cases have been fatal.
- Test patients for HBV infection before initiating treatment with CIMZIA.
- Exercise caution in patients who are carriers of HBV and monitor them before and during CIMZIA treatment.
- Discontinue CIMZIA and begin antiviral therapy in patients who develop HBV reactivation. Exercise caution when resuming CIMZIA after HBV treatment.

NEUROLOGIC REACTIONS

• TNF blockers, including CIMZIA, have been associated with rare cases of new onset or exacerbation of central nervous system and peripheral demyelinating diseases, including multiple sclerosis, seizure disorder, optic neuritis, peripheral neuropathy, and Guillain-Barré syndrome.

HEMATOLOGIC REACTIONS

- Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers. Medically significant cytopenia has been infrequently reported with CIMZIA.
- Consider stopping CIMZIA if significant hematologic abnormalities occur.

DRUG INTERACTIONS

• Do not use CIMZIA in combination with other biological DMARDS.

AUTOIMMUNITY

 Treatment with CIMZIA may result in the formation of autoantibodies and, rarely, in development of a lupus-like syndrome. Discontinue treatment if symptoms of a lupus-like syndrome develop.

IMMUNIZATIONS

• Patients on CIMZIA should not receive live or live-attenuated vaccines.

ADVERSE REACTIONS

• The most common adverse reactions in CIMZIA clinical trials (≥8%) were upper respiratory infections (18%), rash (9%), and urinary tract infections (8%).



